
Xiaoban Xin
Professional Bio
With years of experience as a biomedical researcher, Dr. Xiaoban Xin assists companies and research institutes with building, managing, and protecting their patent assets, strategic patent counseling, and due diligence. Xiaoban has specific experience working with clients in the fields of biotechnology, including gene editing (e.g., CRISPR technology), next generation sequencing, immunotherapy, cell therapy, biologics, stem cells, genetically modified animals, and pharmaceutical formulations, as well as medical device and health IT.
Rehearing Denied in Federal Circuit’s Ruling Against Tecfidera® Patent for Lack of Written Description
Biosimilars Law Bulletin ·
Is Silence Disclosure?
Biosimilars Law Bulletin ·
PTAB Agrees to Review Novartis’ Patent for an Ophthalmic Injection Syringe
Biosimilars Law Bulletin ·